Ionis Pharmaceuticals Inc (NASDAQ: IONS) on Tuesday, soared 1.82% from the previous trading day, before settling in for the closing price of $28.51. Within the past 52 weeks, IONS’s price has moved between $23.95 and $52.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -5.56%. The company achieved an average annual earnings per share of -24.46%. With a float of $154.57 million, this company’s outstanding shares have now reached $157.91 million.
Let’s determine the extent of company efficiency that accounts for 1069 employees. In terms of profitability, gross margin is 96.82%, operating margin of -67.36%, and the pretax margin is -65.23%.
Ionis Pharmaceuticals Inc (IONS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ionis Pharmaceuticals Inc is 2.76%, while institutional ownership is 100.36%. The most recent insider transaction that took place on Apr 16 ’25, was worth 19,292. In this transaction EVP, Corp and Development Ops of this company sold 680 shares at a rate of $28.37, taking the stock ownership to the 56,660 shares. Before that another transaction happened on Apr 16 ’25, when Company’s EVP, Chf GL Pdt Str Ofcr sold 3,016 for $28.36, making the entire transaction worth $85,534. This insider now owns 11,199 shares in total.
Ionis Pharmaceuticals Inc (IONS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -24.46% per share during the next fiscal year.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Ionis Pharmaceuticals Inc (IONS) is currently performing well based on its current performance indicators. A quick ratio of 8.43 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.54.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.04, a number that is poised to hit -1.07 in the next quarter and is forecasted to reach -2.99 in one year’s time.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Looking closely at Ionis Pharmaceuticals Inc (NASDAQ: IONS), its last 5-days average volume was 1.23 million, which is a drop from its year-to-date volume of 1.72 million. As of the previous 9 days, the stock’s Stochastic %D was 90.48%. Additionally, its Average True Range was 1.51.
During the past 100 days, Ionis Pharmaceuticals Inc’s (IONS) raw stochastic average was set at 31.46%, which indicates a significant decrease from 94.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.66% in the past 14 days, which was higher than the 46.74% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.02, while its 200-day Moving Average is $38.08. However, in the short run, Ionis Pharmaceuticals Inc’s stock first resistance to watch stands at $29.41. Second resistance stands at $29.78. The third major resistance level sits at $30.26. If the price goes on to break the first support level at $28.56, it is likely to go to the next support level at $28.08. Now, if the price goes above the second support level, the third support stands at $27.71.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Key Stats
Market capitalization of the company is 4.61 billion based on 158,965K outstanding shares. Right now, sales total 705,140 K and income totals -453,900 K. The company made 226,580 K in profit during its latest quarter, and -104,350 K in sales during its previous quarter.
